Skip to main content
Top
Published in: Indian Journal of Hematology and Blood Transfusion 3/2019

01-07-2019 | Images

Unusual Sites of Auer Rod in AML with t(8;21)

Author: Yi Feng

Published in: Indian Journal of Hematology and Blood Transfusion | Issue 3/2019

Login to get access

Excerpt

A 37-year-old woman was admitted to our hospital with fever for 3 days. She had a history of gestational hypertension and psoriasis. Her peripheral blood cell count showed 75 g/L hemoglobin, 51 × 109/L platelets, and 5.5 × 109/L leukocytes. The differential count showed 22% neutrophils, 15% lymphocytes, 2% eosinophils, 10% monocytes, and 51% blasts. Bone marrow aspiration with Wright-Giemsa stained revealed hypercellularity with 53% blasts and eosinophilia (12%), as well as numerous Auer rods in eosinophils, sea-blue cells, and phagocytes (Fig. 1a–d; original magnification 1000 ×). Flow cytometry analysis demonstrated blasts positive for CD33, CD13, cMPO, HLA-DR, CD117, CD34, CD38. The cytogenetics test found a 45, X, −X, t(8:21) (q22;q22)[20] karyotype, and molecular study showed RUNX1RUNX1T1 rearrangement suggestive of AML with t(8;21).
Literature
1.
go back to reference Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al (2008) WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. IARC Press, Lyon Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al (2008) WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. IARC Press, Lyon
Metadata
Title
Unusual Sites of Auer Rod in AML with t(8;21)
Author
Yi Feng
Publication date
01-07-2019
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion / Issue 3/2019
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-019-01122-9

Other articles of this Issue 3/2019

Indian Journal of Hematology and Blood Transfusion 3/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine